Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kezar Life Sciences, Inc. (KZR : NSDQ)
 
 • Company Description   
Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California.

Number of Employees: 56

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.54 Daily Weekly Monthly
20 Day Moving Average: 1,635,891 shares
Shares Outstanding: 60.42 (millions)
Market Capitalization: $334.70 (millions)
Beta: 0.50
52 Week High: $18.55
52 Week Low: $4.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -59.26% -55.40%
12 Week -61.55% -56.79%
Year To Date -66.87% -59.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4000 SHORELINE COURT SUITE 300
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-822-5600
fax: -
ir@kezarbio.com http://www.kezarlifesciences.com
 
 • General Corporate Information   
Officers
John Fowler - Chief Executive Officer and Director
Jean-Pierre Sommadossi - Chairman
Marc Belsky - Chief Financial Officer and Secretary
Franklin Berger - Director
Graham Cooper - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 49372L100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 60.42
Most Recent Split Date: (:1)
Beta: 0.50
Market Capitalization: $334.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.19 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.35
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -4.00%
vs. Previous Quarter: -4.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -33.99
12/31/21 - -37.23
09/30/21 - -38.69
ROA
03/31/22 - -31.15
12/31/21 - -34.10
09/30/21 - -35.74
Current Ratio
03/31/22 - 35.25
12/31/21 - 25.77
09/30/21 - 15.85
Quick Ratio
03/31/22 - 35.25
12/31/21 - 25.77
09/30/21 - 15.85
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.10
12/31/21 - 4.01
09/30/21 - 2.48
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.04
12/31/21 - 0.05
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 4.00
12/31/21 - 4.66
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©